NEW YORK (GenomeWeb News) – BioMerieux subsidiary BioTheranostics said today that it has signed up Spain's Ferrer InCode to market its molecular diagnostic cancer test in Spain, Portugal, Greece, and Venezuela.
Under the agreement, Ferrer InCode will market BioTheranostics’ Theros CancerTYPE ID molecular cancer classifier. The test is a 92-gene assay that oncologists may use in their efforts to manage patients whose primary tumor sites are not known, otherwise known as cancers of unknown primary origin, or CUP.
BioTheranostics said that around three to five percent of cancers diagnosed worldwide are classified as CUP, which can cause doctors difficulties in trying to develop their treatment plans.
Ferrer InCode, the biotech subsidiary of Grupo Ferrer International, plans to begin marketing the tests immediately, BioTheranostics said.